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Abstract: The macrocyclic tetrapeptide cyclo[Phe-d-Pro-Phe-Trp] (CJ-15,208) and its stereoisomer
cyclo[Phe-d-Pro-Phe-d-Trp] exhibit different opioid activity profiles in vivo. The present study
evaluated the influence of the Phe residues’ stereochemistry on the peptides’ opioid activity.
Five stereoisomers were synthesized by a combination of solid-phase peptide synthesis and
cyclization in solution. The analogs were evaluated in vitro for opioid receptor affinity in radioligand
competition binding assays, and for opioid activity and selectivity in vivo in the mouse 55 ◦C
warm-water tail-withdrawal assay. Potential liabilities of locomotor impairment, respiratory
depression, acute tolerance development, and place conditioning were also assessed in vivo. All of the
stereoisomers exhibited antinociception following either intracerebroventricular or oral administration
differentially mediated by multiple opioid receptors, with kappa opioid receptor (KOR) activity
contributing for all of the peptides. However, unlike the parent peptides, KOR antagonism
was exhibited by only one stereoisomer, while another isomer produced DOR antagonism.
The stereoisomers of CJ-15,208 lacked significant respiratory effects, while the [d-Trp]CJ-15,208
stereoisomers did not elicit antinociceptive tolerance. Two isomers, cyclo[d-Phe-d-Pro-d-Phe-Trp]
(3) and cyclo[Phe-d-Pro-d-Phe-d-Trp] (5), did not elicit either preference or aversion in a conditioned
place preference assay. Collectively, these stereoisomers represent new lead compounds for further
investigation in the development of safer opioid analgesics.
Keywords: opioid peptide; macrocyclic tetrapeptide; multifunctional ligands; structure-activity
relationships; kappa opioid receptor; delta opioid receptor; analgesics; opioid liabilities
1. Introduction
The endogenous opioid system is a valuable therapeutic target for the treatment of pain as it
is extensively involved in pain perception and experience [1]. The majority of opioid ligands used
clinically for the treatment of pain are mu-opioid receptor (MOR) agonists, although agonists of kappa
(KOR) and delta (DOR) receptors also produce analgesia. However, opioid-selective agonists also
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produce a number of undesirable opioid-related side effects that complicate their therapeutic utility.
MOR-selective agonists are reinforcing, and produce analgesic tolerance and respiratory depression [2].
In contrast, KOR selective agonists produce dysphoria, sedation, and psychotomimetic effects [3],
while DOR-selective agonists can induce seizure activity [4].
Multifunctional opioids, ligands with mixed agonist and/or antagonist activity at one or more
opioid receptor, have demonstrated potent antinociception, possibly due to synergistic effects [5].
Co-administration of either KOR [6,7] or DOR [8] agonists enhanced the antinociceptive effects of
MOR-selective agonists. Some multifunctional opioids also produce reduced side effects [9], a profile
attributed to simultaneous modulation of more than one opioid receptor that may counter their
individual adverse effects [10]. For example, KOR agonism offsets MOR-mediated reinforcement [11]
and respiratory depression [12], while DOR antagonism may slow the development of MOR agonist
analgesic tolerance [13,14].
Multifunctional opioid activity has been observed for the structurally distinct macrocyclic
tetrapeptide natural product CJ-15,208 (cyclo[Phe-d-Pro-Phe-Trp], Figure 1). Originally isolated from
the fungus Ctenomyces serratus, initial testing found this peptide preferentially bound to KOR and
antagonized this receptor in the electrically stimulated rabbit vas deferens [15]. When originally isolated
the stereochemistry of the tryptophan residue was not determined, prompting us to synthesize both
the l- and d-Trp stereoisomers [16,17]; the optical rotation of the l-Trp isomer was consistent with
that reported for the natural product. The two isomeric peptides exhibited similar affinity for opioid
receptors (see Table 1) and antagonized KOR in the GTPγS assay in vitro [16–19]. However, the peptides
exhibited distinctly different opioid activity profiles when evaluated in vivo [19]. The d-Trp isomer
primarily exhibited KOR antagonism with modest antinociception only at elevated doses, while the
l-Trp-containing peptide exhibited mixed, multifunctional activity, with robust antinociception
mediated by both KOR and MOR, followed by KOR-selective antagonism lasting several hours
after the dissipation of antinociception. Both of these macrocyclic tetrapeptides are active after oral
administration [20,21], increasing their potential as leads for drug discovery.
Therefore, we explored the influence of the stereochemistry of the two phenylalanine residues in
CJ-15,208 and [d-Trp]CJ-15,208 (cyclo[Phe-d-Pro-Phe-d-Trp]) on opioid activity. All of the stereoisomers
retained significant antinociception with reduced liabilities, while the different stereochemistries of




The stereoisomers of CJ-15,208 and its d-Trp isomer (Figure 1) were synthesized by a combination
of solid phase synthesis of the linear precursors followed by cyclization in solution using modifications
to our original strategy [20,22] to improve the yields of the macrocyclic peptides.
The linear sequences chosen contained the turn inducing D-Pro residue in the middle of the
peptide to facilitate cyclization [17], and the use of the 2-chlorotrityl chloride resin minimized the
potential for diketopiperazine formation. The peptides were purified by silica gel flash chromatography,
which permitted the facile purification of larger quantities of the macrocyclic peptides for in vivo
pharmacological evaluation following oral administration. The purified peptides were analyzed by
electrospray ionization mass spectrometry, thin layer chromatography, and in two analytical HPLC
systems. All of the stereoisomers were obtained in high purity and reasonable yields (34–50% from the
linear precursors) after purification.
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Figure 1. Structures of stereoisomers of CJ-15,208 and [D-Trp]CJ-15,208 
2.2. Metabolic Stability 
We evaluated the metabolic stability of the stereoisomers in mouse liver microsomes. While 
macrocyclic peptides are stable to proteases, they can be metabolized by cytochrome P450 enzymes 
[23,24]. In all cases the peptides were stable in incubations lacking NADPH, but disappeared from 
the incubations containing NADPH, consistent with cytochrome P450 enzyme metabolism. The half-
lives of the stereoisomers in the mouse liver microsomes were ≤ 30 min for all of the stereoisomers 
except for 1, which displayed a half-life more than twice that of most of the other stereoisomers 
(Figure 2). The short half-lives of most of the stereoisomers are consistent with that of [D-Trp]CJ-
15,208 (11 min), while the longer half-life of stereoisomer 1 is similar to that of CJ-15,208 (49 min) 










Figure 1. Structures of stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208.
2.2. Metabolic Stability
We evaluated the metabolic stability of the stereoisomers in mouse liver microsomes.
While macrocyclic peptides are stable to proteases, they can be metabolized by cytochrome P450
enzymes [23,24]. In all cases the peptides were stable in incubations lacking NADPH, but disappeared
from the incubations containing NADPH, consistent with cytochrome P450 enzyme metabolism.
The half-lives of the stereoisomers in the mouse liver microsomes were ≤30 min for all of the
stereoisomers except for 1, which displayed a half-life more than twice that of most of the other
stereoisomers (Figure 2). The short half-lives of most of the stereoisomers are consistent with that of
[d-Trp]CJ-15,208 (11 min), while the longer half-life of stereoisomer 1 is similar to that of CJ-15,208
(49 min) (Khaliq et al., manuscript in preparation).
Molecules 2020, 25, x FOR PEER REVIEW 3 of 19 
 
  
Figure 1. Structures of stereoisomers of CJ-15,208 and [D-Trp]CJ-15,208 
2.2. Metabolic Stability 
We evaluated the metabolic stability of the stereoisomers in mouse liver microsomes. While 
macrocyclic peptides are stable to proteases, they can be metabolized by cytochrome P450 enzymes 
[23,24]. In all cases the peptides were stable in incubations lacking NADPH, but disappeared from 
the incubations containing NADPH, consistent with cytochrome P450 enzyme metabolism. The half-
lives of the stereoisomers in the mouse liver microsomes were ≤ 30 min for all of the stereoisomers 
except for 1, which displayed a half-life ore than twice that of most of the other stereoisomers 
(Figure 2). T e short half-lives of most of the stereoisomers are consistent with that of [D-Trp]CJ-
15,208 (11 min), while the longer half-life of stereoisomer 1 is similar to that of CJ-15,208 (49 min) 

















Figure 2. Metabolic stability in mouse liver microsomes of the stereoisomers: (A) 1, (B) 2, (C) 3, (D) 4 
and (E) 5. 
2.3. In Vitro Pharmacological Evaluation 
In radioligand equilibrium competition binding assays the D-Phe stereoisomers of CJ-15,208 and 
[D-Trp]CJ-15,208 generally exhibited greatly reduced affinity for KOR and MOR compared to the two 
parent peptides (Table 1). Only the D-Phe3 analogs (see Figure 1 for residue numbering) exhibited 
sub-micromolar affinity for any of the opioid receptors (Ki = ~350 nM for KOR). Similar to CJ-15,208 
and [D-Trp]CJ-15,208 [19], the stereoisomers all exhibited negligible affinity for DOR. Also consistent 
with the results for CJ-15,208 and [D-Trp]CJ-15,208, none of the analogs exhibited appreciable efficacy 
at either KOR or MOR at 10 μM in [35S]GTPγS assays. 
Table 1. Opioid receptor affinities of the stereoisomers of CJ-15,208 and [D-Trp]CJ-15,208 a,b. 
Stereoisomer 
Ki (nM ± SEM) Selectivity 
KOR MOR 
Ki (MOR)  
Ki (KOR) 
1 (D-Phe1) 5120 ± 690 >10,000 <2 
2 (D-Phe3) 362 ± 51 3920 ± 200 11 
3 (D-Phe1,3) 2560 ± 480 7780 ± 410 3 
CJ-15,208 27.4 ± 4.6 451 ± 114 16.5 
4 (D-Phe1, D-Trp4) >10,000 >10,000 - 
5 (D-Phe3, D-Trp4) 353 ± 19 5800 ± 1450 16 
[D-Trp4]CJ-15,208 21.8 ± 4.8 259 ± 29 12 
a Data are the mean Ki values ± SEM from at least three experiments. b None of the stereoisomers at 10 
μM exhibited appreciable affinity for DOR (<30% inhibition of [3H]cyclo[D-Pen2,D-Pen5]enkephalin 
(DPDPE) binding). 
2.4. In Vivo Pharmacological Evaluation 
The stereoisomers were initially evaluated for their antinociceptive activity in the 55 °C warm-
water tail-withdrawal assay in C57BL/6J mice following i.c.v. administration (Figures 3A and S1). All 
of the D-Phe stereoisomers produced significant time- and dose-dependent antinociception (p < 0.05, 
two-way RM ANOVA). Peak antinociception was produced 20 min after i.c.v administration for 
stereoisomers 1, 3, and 4 and at 30 min for isomers 2 and 5 (Figure S1). The duration of significant 
antinociception (p < 0.05; Dunnett’s post hoc test) varied from 45 min (isomers 3 and 4) to 90 min 
(isomers 2 and 5), with isomer 1 exhibiting an intermediate duration. All of the isomers exhibited full 
and potent antinociception except for 2 (Figure 3A), which produced approximately 70% 
antinociception at the highest dose tested (100 nmol); the potencies of stereoisomers 1 and 3–5 were 
comparable to that of CJ-15,208 (Table 2). The maximal antinociception found for the stereoisomers 4 
Figure 2. Metabolic stability in mouse liver microsomes of the stereoisomers: (A) 1, (B) 2, (C) 3, (D) 4
and (E) 5.
2.3. In Vitro Pharmacological Evaluation
In radioligand equilibrium competition binding assays the d-Phe stereoisomers of CJ-15,208 and
[d-Trp]CJ-15,208 generally exhibited greatly reduced affinity for KOR and MOR compared to the two
parent peptides (Table 1). Only the d-Phe3 analogs (see Figure 1 for residue numbering) exhibited
sub-micromolar affinity for any of the opioid receptors (Ki = ~350 nM for KOR). Similar to CJ-15,208
and [d-Trp]CJ-15,208 [19], the stereoisomers all exhibited negligible affinity for DOR. Also consistent
with the results for CJ-15,208 and [d-Trp]CJ-15,208, none of the analogs exhibited appreciable efficacy
at either KOR or MOR at 10 µM in [35S]GTPγS assays.
Table 1. Opioid receptor affinities of the stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208 a,b.
Stereoisomer
Ki (nM ± SEM) Selectivity
KOR MOR Ki (MOR)Ki (KOR)
1 (d-Phe1) 5120 ± 690 >10,000 <2
2 (d-Phe3) 362 ± 51 3920 ± 200 11
3 (d-Phe1,3) 2560 ± 480 7780 ± 410 3
CJ-15,208 27.4 ± 4.6 451 ± 114 16.5
4 (d-Phe1, d-Trp4) >10,000 >10,000 -
5 (d-Phe3, d-Trp4) 353 ± 19 5800 ± 1450 16
[d-Trp4]CJ-15,208 21.8 ± 4.8 259 ± 29 12
a Data are the mean Ki values ± SEM from at least three experiments. b None of the stereoisomers at 10 µM exhibited
appreciable affinity for DOR (<30% inhibition of [3H]cyclo[d-Pen2,d-Pen5]enkephalin (DPDPE) binding).
2.4. In Vivo Pharmacological Evaluation
The stereoisomers were initially evaluated for their antinociceptive activity in the 55 ◦C warm-water
tail-withdrawal assay in C57BL/6J mice following i.c.v. administration (Figure 3A and Figure S1). All of
the d-Phe stereoisomers produced significant time- and dose-dependent antinociception (p < 0.05,
two-way RM ANOVA). Peak antinociception was produced 20 min after i.c.v administration for
stereoisomers 1, 3, and 4 and at 30 min for isomers 2 and 5 (Figure S1). The duration of significant
antinociception (p < 0.05; Dunnett’s post hoc test) varied from 45 min (isomers 3 and 4) to 90 min (isomers
2 and 5), with isomer 1 exhibiting an intermediate duration. All of the isomers exhibited full and
potent antinociception except for 2 (Figure 3A), which produced approximately 70% antinociception at
the highest dose tested (100 nmol); the potencies of stereoisomers 1 and 3–5 were comparable to that of
CJ-15,208 (Table 2). The maximal antinociception found for the stereoisomers 4 and 5 of [d-Trp]CJ-15,208
is in contrast to the parent peptide, which exhibits minimal antinociceptive activity [19].
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Pretreatment of mice with an opioid antagonist was used to assess receptor contribution to the 
observed antinociception, Naloxone (30 mg/kg., s.c.) pretreatment (20 min) significantly reduced the 
antinociceptive effects of all five analogs (F(4,61) = 2.68, p < 0.05, two-way ANOVA with Sidak’s post hoc 
test; Figure 4A), consistent with opioid receptors mediating the antinociception. The individual 
receptor contributions to the observed antinociception were then determined by pretreating the mice 
with the selective MOR, KOR and DOR antagonists β-FNA (10 mg/kg, i.p., −24 h), nor-BNI (10 mg/kg, 
i.p., −24 h), or naltrindole (20 mg/kg., i.p., −20 min), respectively, prior to administration of the 
macrocyclic tetrapeptide (isomers 1, 3, 4 and 5 at 10 nmol, and isomer 2 at 100 nmol, i.c.v; Figure 4B). 
Figure 3. Antinociceptive activity in the 55 ◦C warm-water tail-withdrawal assay following (A) i.c.v.
administration and (B) oral administration in C57BL/6J mice. All points represent antinociception at peak
response, which occurred 20–30 min after administration. Points represent average % antinociception
± SEM from 4–16 mice for each set presented.
The d-Phe stereoisomers of CJ-15,208 and of [d-Trp]CJ-15,208 also exhibited significant
antinociceptive effects following oral (p.o.) administration (p < 0.05, two-way RM ANOVA; Figure 3B
and Figure S2). Isomers 1, 3, and 5 produced full antinociception with comparable potency to CJ-15,208
(Table 2) that peaked between 20-30 min, while isomers 2 and 4 produced only 45–60% antinociception
at the highest oral dose tested (30 mg/kg, p.o.). The duration of significant antinociception (p < 0.05,
Dunnett’s post hoc test) was 50–60 min for all stereoisomers except 4 (30–40 min). While isomer 2
exhibited low antinociceptive efficacy by both routes of administration, isomer 4 exhibited decreased
efficacy only following oral administration.
Table 2. Summary of in vivo opioid antinociceptive activity of the stereoisomers a.
Stereoisomer
ED50 (and 95% Confidence Interval (C.I.)) Values
i.c.v. (nmol) p.o. (mg/kg) Receptors Involved
1 0.75 (0.36–1.44) 7.62 (5.12–12.2) KOR, MOR, D R
2 20.4 (10–58.7) ~ KOR, MOR
3 1.00 (0.64–1.60) 4.12 (3.30–5.31) KOR, DOR
CJ-15,208 b,c 1.74 (0.62–4.82) 3.49 (1.98–5.73) KOR, MOR
4 2.39 (1.40–4.56) ~ DOR, KOR
5 0.56 (0.38–0.91) 4.72 (3.70–6.39) KOR, MOR, DOR
[d-Trp4]CJ-15,208 b,d ~ ~ -
a In addition, isomer 1 exhibited antagonist activity at KOR, and isomer 5 exhibited antagonist activity at DOR.
b Ref. [19]; c Ref. [20]; d Ref. [21]. ~ Maximum antinociception not achieved, precluding calculation of a ED50 value.
2.4.1. Opioid Receptor Selectivity of Stereoisomer Antinociception
Pretreatment of mice with an opioid antagonist was used to assess receptor contribution to the
observed antinociception, Naloxone (30 mg/kg., s.c.) pretreatment (20 min) significantly reduced the
antinociceptive effects of all five analogs (F(4,61) = 2.68, p < 0.05, two-way ANOVA with Sidak’s post
hoc test; Figure 4A), consistent with opioid receptors mediating the antinociception. The individual
receptor contributions to the observed antinociception were then determined by pretreating the
mice with the selective MOR, KOR and DOR antagonists β-FNA (10 mg/kg, i.p., −24 h), nor-BNI
(10 mg/kg, i.p., −24 h), or naltrindole (20 mg/kg., i.p., −20 min), respectively, prior to administration
of the macrocyclic tetrapeptide (isomers 1, 3, 4 and 5 at 10 n ol, and isomer 2 at 100 nmol, i.c.v;
Figure 4B). Treatment with these antagonists significantly affected antinociception produced by the
stereoisomers (F(12,159) = 11.2, p < 0.05, two-way ANOVA). β-FNA, nor-BNI, and naltrindole all
significantly antagonized the antinociception of stereoisomers 1 and 5 (p < 0.05, Tukey’s post hoc
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test), suggesting that all three opioid receptors contributed to the antinociception produced by these
stereoisomers. In contrast, isomer 2 demonstrated KOR- and MOR-mediated antinociception, whereas
the antinociception produced by 3 and 4 was KOR- and DOR-mediated (p < 0.05, Tukey’s post hoc test).
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Figure 4. Evaluation of opioid receptor involvement in the antinociceptive activity of the stereoisomers
in the 55 ◦C warm-water tail-withdrawal assay 20 min after (A) p.o. administration in mice pretreated
with the non-selective opioid receptor antagonist naloxone (30 mg/kg., s.c., −20 min), or (B) 20 min
after i.c.v. administration in mice pretreated with the selective MOR antagonist β-FNA (10 mg/kg, i.p.,
−24 h), the selective KOR antagonist nor-BNI (10 mg/kg, i.p., −24 h), or the selective DOR antagonist
naltrindole (20 mg/kg, i.p., −20 min). Points represent average % antinociception ± SEM from 8–16 mice
for each bar. * significantly different from response of stereoisomer alone (p < 0.05. ** two significant
bars adjacent to each other.; two-way ANOVA with (A) Sidak’s or (B) Tukey’s multiple comparisons
post hoc test).
2.4.2. Determination of Stereoisomer Opioid-Receptor Mediated Selective Antagonist Activity
Following dissipation of the antinociception, the stereoisomers were evaluated for antagonist
activity against the KOR-selective agonist U50,488 (10 mg/kg., i.p.), the MOR-preferring agonist
morphine (10 mg/kg, i.p.), and the DOR-selective agonist SNC-80 (100 nmol, i.c.v.; Figure 5). Only isomer
1 (30 nmol, i.c.v.) exhibited significant antagonism of U50,488 (F(5,55) = 5.81, p < 0.05, one-way ANOVA
with Sidak’s post hoc test; Figure 5A). Interestingly, stereoisomer 5 (100 nmol, i.c.v) significantly
antagonized SNC-80 (F(5,55) = 7.71, p < 0.05, one-way ANOVA with Sidak’s post hoc test; Figure 5C),
while none of the peptides demonstrated antagonism against morphine (Figure 5B).
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assay. ice ere pretreated with a stereoisomer (30 or 100 n ol., i.c.v.) 3 h prior to the ad inistration
of ( ) the KOR selective agonist U50,488 (10 g/kg., i.p.), (B) the OR preferring agonist orphine
(10 g/kg., i.p.), or (C) the DOR selective agonist SNC-30 (100 n ol, i.c.v.) to assess their ability to
significantly reduce the antinociceptive effect of the opioid agonist. Mean % antinociception ± SE
fro 8 ice for each bar. * significantly different from response of agonist alone (p < 0.05); one-way
ANOVA with Sidak’s multiple comparison post hoc test.
2.5. In Vivo Assessment of Opioid Related Liabilities
The five stereoisomers were then assessed for several potential liabilities produced by opioid
agonists, specifically impairment of locomotor coordination, respiratory depression, hyperlocomotion
and analgesic tolerance.
2.5.1. Assessment of Effects on Coordinated Locomotor Activity
Treatment with the stereoisomers (10 mg/kg, p.o.) or the KOR-selective agonist U50,488
(10 mg/kg, i.p.) had a significant effect on coordinated locomotor performance in the mouse rotarod
assay (F(6,49) = 7.91; p < 0.05, two-way RM ANOVA) over time (F(6,294) = 13.7; p < 0.05, two-way RM
ANOVA; Figure 6).
Whereas U50,488 significantly impaired coordinated locomotor activity after the first 10 min
compared to vehicle (p < 0.05, Dunnett’s post hoc test), the stereoisomers 2, 3 and 5 lacked any
significant effect, and isomers 1 (at 20, 40 and 50 min) and 4 (at 40 min) displayed limited impairment
of performance (p < 0.05, Dunnett’s post hoc test).
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Figure 6. Effect of the stereoisomers on locomotor coordination after p.o. administration to C57BL/6J
mice in the rotarod assay. Mice received the macrocyclic tetrapeptide (10 mg/kg, p.o.), vehicle
(10% Solutol in saline, p.o.), or U50,488 (10 mg/kg, i.p.) and were tested on the rotarod apparatus with
repeated measurements over time. Latencies to fall are given as the mean % change from baseline
(100%) performance ± SE . n = 8 mice per treatment. * significantly different from response of vehicle
alone (p < 0.05); two-way R ANOVA with Dunnett’s multiple comparison post hoc test.
2.5.2. Evalu tion of Respiratory and Spontaneous Locomotor Effects
The five stereoisomers (10 mg/kg, p.o.) were then assessed for their effect on spontaneous
respiration rates and locomotor activity over a 1 h period using the Comprehensive Laboratory
Animal Monitoring System (CLAMS) (Figure 7). As expected, the positive control morphine produced
significant, time-dependent respiratory depression compared to vehicle (10–30 min; F(10,165) = 2.48,
p < 0.05, two-way RM ANOVA with Dunnett’s multiple comparison post hoc test; Figure S2),
while tr atm nt with U50,488 resulted in significant, time-depen ent increas s in respiration rates
(20–40 and 50–60 min; p < 0.05, Dunnett’s post hoc test; Figure S2). St re isomers 1–3 of CJ-15,208
did not have any significant effect on respiration compared to ve icle (Figure 7A). Conversely,
[d-Trp]CJ-15,208’s isomers 4 and 5 produced significant decreases in respiration rates for the duration
of the 60 min testing period (F(5,50) = 12.9, p < 0.05, wo-way RM ANOVA with Dunne t’s multiple
comparison post hoc est; Figure 7A). Amo g the d-Phe s ereoisomers, only 3 h d a significant effect on
ambulation compared to vehicle, demon trating el vated ambulations at sev al time-points (20–40
and 50–60 min; F(5,47) = 6.20, p < 0.05, two-way RM ANOVA w th Dunnett’s multiple comparison post
hoc test; Figure 7B). The positive control morphin produced obust, significant incr ases in ambulation
over he last 40 min of testing (F(10,215) = 27.2, p < 0.05, two-way RM ANOVA with Dunn tt’s mult ple
comparison post hoc test; Figure S2).
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2.5.3. Assessment of Acute Antinociceptive Tolerance Development
The stereoisomers were also tested in a model of acute antinociceptive tolerance [25] with
repeated dosing (at 0 and 8 h, 0.1–300 nmol, i.c.v.) of morphine, CJ-15,208 or one of the five analogs.
The development of acute antinociceptive tolerance was assessed by pretreating with the ED50 i.c.v.
dose of the test compound, followed 8 h later by treatment with one of a range of graded doses;
antinociceptive tolerance was indicated by a significant increase in the ED50 value compared to the
value observed in naïve animals. As expected, morphine demonstrated acute antinociceptive tolerance,
with a significant 7.63-fold rightward shift in the dose-response curve of the second dose administered
(F(1,4) = 26.2, p < 0.05; non-linear regression analysis; Table 3; see also Figure S3). Neither stereoisomer
4 or 5 demonstrated any significant changes in the ED50 values collected at 8 h vs. 0 h (Table 3).
Both stereoisomers 1 and 3 demonstrated greater acute antinociceptive tolerance than CJ-15,208, with
significant rightward shifts in their second dose-response curves (31.2-fold (F(1,5) = 39.9 p < 0.05)
and 5.19-fold (F(1,5) = 27.3, p < 0.05), respectively; non-linear regression analysis). While isomer 2
demonstrated a 6.13-fold increase in its ED50 value after pretreatment, the increase was not statistically
significant (F(1,4) = 2.99, p = 0.16.)
Table 3. Comparison of ED50 (and 95% C.I.) values in naïve subjects and after again 8 h after a treatment
of an ED50 dose of the respective compound a.





1 0.65 (0.31–1.31) 20.3 * (11.1–41.7) 31.2
2 20.4 (10–58.7) 125 (89.9–224) 6.13
3 1.00 (0.64–1.60) 5.19 * (2.57–11) 5.19
4 2.39 (1.40–4.56) 1.28 (0.96–1.66) 0.54
5 0.45 (0.28–0.70) 0.49 (0.09–1.3 ) 1. 9
CJ-15,208 1.82 (1.22–2.74) 5.23 (4.23–6.48 2.87
Morphine 2.91 (2.48–3.41) 22.2 * (14.0–55.3) 7.63
a Data are ED50 values (nmol) from C57BL/6J mice tested with one of several doses (i.c.v.) of compound in the 55 ◦C
warm-water tail-withdrawal assay in either naïve animals or mice who were pretreated with the ED50 dose of the
respective compound, followed by administration of varying doses 8 h later. * significantly different from ED50
value in naïve mice (p < 0.05), non-linea regression analysis. n = 8–16 mice/do e tested.
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2.5.4. Evaluation of Potential Reinforcing or Aversive Properties
Analogs 3 and 5 were further evaluated in a conditioned place-preference assay (Figure 8).
Following a two-day place conditioning paradigm, mice conditioned with morphine (10 mg/kg,
i.p.) demonstrated a significant place-preference for the morphine-paired chamber, whereas mice
conditioned with U50,488 (10 mg/kg, i.p.) demonstrated a significant conditioned place avoidance
(F(3,53) = 5.38, p < 0.05; two-way ANOVA with Sidak’s multiple comparison post hoc test; Figure 8).
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counterbalanced design. Data is presented as mean difference in time spent on the drug-paired side ±
SEM, with positive and negative values indicating a preference for and avoidance of the drug-paired
chamber, respectively. * significantly different from matching preconditioning preference (p < 0.05),
two-way ANOVA. n = 14–28 mice/compound.
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3. iscussion
The acrocyclic tetrapeptide CJ-15,208 is structurally distinct from the endogenous opioid peptides,
representing a novel lead compound for the development of new ligands for KOR. Its structure is
particularly appealing for modification because its small macrocyclic structure imparts stability to
degradation by proteases and facilitates penetration of biological barriers, including both the intestinal
and blood-brain barriers [20,21] (Khaliq et al., manuscript in preparation), facilitating systemic, even
oral, administration.
hanges in stereoche istry had differential effects on the contributions of the three opioid
receptors to antinociception in vivo. hile all three aro atic residues of J,15-208 ere previously
found to be i portant for KOR agonist activity [26], all of the stereoisomers, including the isomers
of [d-Trp]CJ-15,208, exhibited KOR agonist activity in vivo regardless of residue stereochemistry.
In contrast, only stereoisomer 1 retained KOR antagonist activity. Unlike the parent co pounds, all of
the stereoiso ers except 2 e onstrate antinociception also ediated in part by . his is in
contrast to the in vitro results, here the stereoiso ers all lacked affinity for in radioligand
binding assays; such discrepancies bet een in vitro and in vivo activity have been found for other
J-15,208 analogs [26–28]. d-Phenylalanine in position 1 appears to favor DOR agonist activity;
of the four isomers where DOR contributes to the observed antinociception only 5 does not contain
d-Phe1, and DOR appears to contribute less to the antinociception of this isomer than for the other
isomers (Figure 4B). MOR contributes to the antinociception of three of the stereoisomers, but not to
antinociception produced by isomers 3 and 4. The lack of MOR contribution in these peptides cannot
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be attributed to the change in stereochemistry of any specific residue; it may instead be related to
differences in peptide backbone conformation and the resulting effect on the orientation of one or more
of the aromatic residues. Thus only isomer 2 retained the mixed MOR/KOR agonism of CJ-15,208,
but this isomer did not exhibit maximum antinociception nor KOR antagonist activity.
All of the stereoisomers retained antinociceptive activity following oral administration, despite
the rapid metabolism of most of these peptides by liver microsomes. Such hydrophobic peptides,
including the parent peptides (Khaliq et al., manuscript in preparation), generally have high plasma
protein binding which can protect compounds from metabolism and clearance, and thereby extend the
duration of their activity in vivo. Only in the case of isomer 4 was there a difference in the maximum
antinociception following oral vs. central administration. The decreased maximum response and
shorter duration following oral administration for this isomer are likely due to its pharmacokinetic
properties (metabolism, clearance and/or intestinal absorption).
The stereoisomers exhibited different potential liabilities of use. While KOR agonism contributed to
the antinociception of all of the stereoisomers, in the rotarod assay only isomer 5 exhibited significantly
decreased locomotor coordination at multiple time points, suggesting that activity at multiple opioid
receptors mitigated this known side effect of KOR agonists. The lack of significant decreases in
respiratory rates for all three CJ-15,208 isomers was very promising. We have previously shown
that the multifunctional macrocyclic tetrapeptide cyclo[Pro-Sar-Phe-d-Phe] exhibits reduced liabilities,
particularly respiratory effects, and that the peptide’s KOR agonist activity appears to offset respiratory
depression mediated by MOR [9]. In contrast, treatment with [d-Trp]CJ-15,208 isomers 4 and 5
decreased respiratory rates; this effect of 4 was surprising, given the lack of MOR agonist activity by
this isomer. While not significant, there was a trend towards decreased ambulation following treatment
with 4 and 5, so it is possible that the decreased respiration rates could be due in part to decreased
movement by these mice. In contrast to their effects on respiration rates, neither of the [d-Trp]CJ-15,208
stereoisomers exhibited evidence of acute tolerance, while, unlike the parent peptide, the CJ-15,208
isomers exhibited rightward shifts of the dose-response curves to varying degrees. Thus there was a
dichotomy between the liabilities observed for the CJ-15,208 stereoisomers, which lacked respiratory
depression but exhibited variable acute tolerance, and the [d-Trp]CJ-15,208 isomers, that exhibited the
opposite pattern of decreased respiratory rates, but without significant acute tolerance.
Two isomers, 3 and 5, were selected for testing in the conditioned place-preference assay for
reinforcing (conditioned place preference, CPP) or aversive (conditioned place aversion, CPA) effects.
Among the CJ-15,208 isomers, 3 demonstrated the most promising activity, producing full antinociception
without locomotor impairment or respiratory effects, while the [d-Trp]CJ-15,208 isomer 5 produced
full antinociception without acute antinociceptive tolerance. Mice place conditioned with either
isomer demonstrated no significant preference or aversion for their respective drug-paired chamber.
These results are consistent with earlier tests of multifunctional macrocyclic tetrapeptides [9,19] and could
reflect the counteracting effects of agonism at multiple opioid receptors such as MOR and KOR [9,10].
In contrast to 5, isomer 3 did not demonstrate significant MOR-mediated agonism, but rather KOR- and
DOR-mediated antinociception. Mixed action DOR/MOR agonists such as MMP-2200 reportedly do
not produce CPP and exhibit limited reinforcing effects [29]. Isomer 5 also displayed DOR antagonism
which has been shown to prevent the conditioned place preference of MOR agonists in studies of
bivalent ligands [30] and peptidomimetics [31]. To the best of our knowledge, no one has examined
the effect of combined KOR agonists/DOR agonists or antagonists. Additional testing of higher doses
of 3 and 5 are required to confirm the absence of the place conditioning demonstrated here.
The liabilities of the different stereoisomers did not correlate with the receptor involvement
determined in the antinociceptive assay. The antinociception of both the CJ-15,208 stereoisomer 3 and
the [d-Trp]CJ-15,208 isomer 4 were mediated by DOR and KOR, without significant contribution from
MOR, but these peptides had opposite liability profiles. The same was true for stereoisomers 1 and 5,
where agonist activity mediated by all three opioid receptors contribute to the observed antinociception.
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Additional studies will be necessary to explore potential mechanisms for the observed agonist
(and in two cases antagonist) activity of these stereoisomers and to better understand receptor
contributions to the observed side effects. Such studies are currently ongoing in our laboratories.
The stereoisomer [d-Phe1,3]CJ-15,208 (3) is a very promising new lead compound for further
exploration. Its potent antinociception after oral administration and lack of respiratory depression or
locomotor impairment holds significant promise for the identification of safer analgesics.
4. Materials and Methods
4.1. Chemicals
The sources of the reagents, amino acids, solid phase resin and solvents for peptide synthesis are
the same as reported previously [17,26,27]. Amino acids are the l-isomer unless otherwise specified,
and abbreviations for amino acids follow the IUPAC-IUB joint commission of biochemical nomenclature
(Eur. J. Biochem. 1984, 138, 9–37). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Thin layer chromatography was performed on glass backed precoated silica gel plates (Sorbent
Technologies, Atlanta, GA, USA, or Whatman, aluminum backed, 250 µm layer, Fisher Scientific,
Pittsburg, PA, USA), and flash chromatography was performed on standard grade (32–63 µm) silica gel
(Sorbent Technologies). HPLC analysis was performed on a Vydac 218TP C18 reversed phase column
(Grace Davison, Columbia, MD, USA, 4.6 × 50 mm, 5 µm).
4.2. Instruments
Electrospray ionization mass spectra were acquired on a LCT Premier time of flight mass
spectrometer (Waters Corp., Milford MA, USA) at the University of Kansas. HPLC analysis was
performed using an Agilent 1200 HPLC system (Agilent, Santa Clara, CA, USA).
4.3. Peptide Synthesis and Purification
The linear peptide precursors (based on the parent sequences l-/d-Trp-Phe-d-Pro-Phe-OH) were
synthesized on a 2-chlorotrityl chloride resin by Fmoc (fluorenylmethoxycarbonyl) peptide synthesis,
and the peptides cleaved from the resin with 1% trifluoroacetic acid (TFA) in dichloromethane as
described previously [17,26,27]. The crude linear peptides were cyclized using the following general
procedure [20,22,27]: The crude linear peptide (0.5 equiv, 21 mM in N,N-dimethylformamide, DMF)
was added dropwise at a rate of 1.0 mL/h (using a KD Scientific single infusion syringe pump) to a dilute
solution of HATU (2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate,
0.75 equiv, 1.2 mM) and N,N-diisopropylethylamine (DIEA, 4 equiv, 5 mM) in DMF. After 15 h
additional HATU (0.75 equiv) was then added to the reaction in one portion, and additional linear
peptide (0.5 equiv, 21 mM in DMF) was added dropwise at a rate of 1.0 mL/h as described above to
give a final concentration of the linear tetrapeptide of 2.5 mM. The reaction was then stirred for 6 h at
room temperature, followed by an additional 24 h at 37 ◦C. The solvent was evaporated under reduced
pressure, and the crude macrocyclic tetrapeptides isolated as previously described [17,20,26].
The crude peptides were purified by silica gel chromatography using a step gradient of 60–90%
EtOAc in hexane (with EtOAc increased in 10% increments), followed by 0–10% MeOH in EtOAc (with
MeOH increased in 1% increments). The purified peptides were dissolved in aqueous acetonitrile
(water:MeCN, 4:1) and then lyophilized to give the pure peptides as white solids. The purified
peptides were analyzed by electrospray ionization mass spectrometry, thin layer chromatography,
and in two analytical HPLC systems (see Table 4). The peptides were all >98% pure in both HPLC
systems except for 4 which exhibited slightly lower purity. HPLC chromatograms are included in the
Supplementary Materials.
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Table 4. Analytical data for stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208.
Observed TLC HPLC, t (min)
Isomer ES-MS, m/z a Rf b System A c System B d
1 600.2568 0.70 18.4 23.0
2 600.2565 0.10 18.9 –
3 600.2578 0.67 22.4 22.6
4 600.2584 0.49 18.6 e 21.9 e
5 600.2605 0.53 21.1 23.8
a M + Na+, calculated m/z 600.2587; b EtOAc: MeOH, 9:1; c 15–55% MeCN over 40 min with 0.1% TFA, detection at
214 nm; d 30–70% MeOH over 45 min with 0.1% TFA, detection at 230 nm. e 94% and 96% pure in systems A and
B, respectively.
4.3.1. [d-Phe1]CJ-15,208 (1)
Cyclization of the linear peptide (600 mg) according to the general procedure yielded stereoisomer
1 as a white solid (193 mg, 34% yield).
4.3.2. [d-Phe3]CJ-15,208 (2)
The linear peptide (400 mg) was cyclized according to the general procedure, except that the
second addition of peptide was added at a rate of 0.8 mL/h and the final concentration of the linear
peptide in the reaction mixture was 4.5 mM. The peptide was purified starting at 60% EtOAc in hexane
as described above, followed by 0–30% MeOH in EtOAc (with MeOH increased in 3% increments) to
yield stereoisomer 2 as a white solid (167 mg, 43% yield).
4.3.3. [d-Phe1,3]CJ-15,208 (3)
Cyclization of the linear peptide (600 mg) was performed according to the general procedure
above. The purification was performed starting at 50% EtOAc in hexane (with EtOAc increased in 10%
increments), followed by 0–5% MeOH in EtOAc (with MeOH increased in 1% increments) to yield 3 as
a white solid (294 mg, 50% yield).
4.3.4. [d-Phe1,d-Trp4]CJ-15,208 (4)
The linear peptide (400 mg) was cyclized according to the general procedure above, except that
the first addition of peptide was added at a rate of 1.2 mL/h and the final concentration of the linear
peptide in the reaction mixture was 1.5 mM. The purification was performed starting at 30% EtOAc in
hexane (with EtOAc increased in 10% increments), followed by 0–3% MeOH in EtOAc (with MeOH
increased in 1% increments) to yield 4 as a white solid (174 mg, 45% yield).
4.3.5. [d-Phe3,d-Trp4]CJ-15,208 (5)
The linear peptide (430 mg) was cyclized according to the general procedure, except that the
second addition of peptide was added at a rate of 0.8 mL/h and the final concentration of the linear
peptide in the reaction mixture was 3.6 mM. The peptide was purified starting at 60% EtOAc in hexane
as described above, followed by 0–5% MeOH in EtOAc (with MeOH increased in 5% increments) to
yield stereoisomer 5 as a white solid (200 mg, 48% yield).
4.4. Metabolism by Mouse Liver Microsomes
The macrocyclic tetrapeptide (5 µM) in 1% acetonitrile was incubated with mouse liver microsomes
(0.25 mg/mL protein, Xenotech, Lenexa, KS, USA) at 37 oC in the presence or absence of co-factor NADPH
RapidStart System (1 mM, Xenotech) or NADPH solution (Sigma, St. Louis, MO, USA) in potassium
phosphate buffer (50 mM, pH 7.4). Aliquots (100 µL) taken at 0, 5, 15, 30, 60 and 120 min were quenched
with ice-cold acetonitrile (1 vol) containing internal standard ([d-NMeAla2]CJ-15,208 [26], 5 µM) to
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precipitate the proteins. The lack of endogenous interference with the analysis of the stereoisomer or
internal standard was confirmed by analyzing samples lacking the macrocyclic tetrapeptide.
Following centrifugation at 10,000× g rpm for 10 min, the supernatant (50 µL) was diluted with
water (75 µL), stored overnight at −20 ◦C and analyzed by LC-MS/MS using methodology similar to
that described for [d-Trp]CJ-15,208 [32]. Liquid chromatography was performed on a Hypersil BDS
C8 column (50 mm × 2.1 mm, 3 µm) with a flow rate of 0.2 mL/min and an injection volume of 20 µL
using an Acquity UPLC system (Waters, Milford, MA, USA). The peptides were separated using a
gradient of aqueous acetonitrile containing 0.08% formic acid of 20% B (0–2 min), 20–50% B (2–3 min),
50–80% B (3–6 min), 80% B (6–7 min), 80–20% B (7–8 min) and 20% B (8–10 min).
ESI-MS/MS was performed on a Waters Quatro triple quadrupole instrument operating in the
positive ion multiple reaction monitoring mode. Data acquisition was carried out with Mass Lynx 4.1
software with the following settings: capillary voltage, 2500 V; cone voltage, 30 V; source temperature,
100 ◦C; desolvation temperature, 250 ◦C; cone gas flow, 279 L/h; desolvation gas flow, 1157 L/h; LM 1
resolution, 14; HM 1 resolution, 14; ion energy 1, 1.0; MS/MS mode entrance, -1; MS/MS collision
energy, 35 eV; MS/MS mode exit, 2; LM 2 resolution, 13.0; HM 2 resolution, 13.0; ion energy 2, 1.5;
multiplier, 650; collision cell pressure, 1.63 × 10−3 mbar; collision gas, argon. The transition m/z 578.2
([M + H]+)→ 217.2 was monitored to determine the peak area counts of the stereoisomers, and m/z
566.2 ([M + H]+)→ 232.9 was monitored to determine the peak area counts of the internal standard
(collision energy 22 eV) with the following settings: dwell time, 0.3 s; delay, 0.05 s.
4.5. In Vitro Pharmacological Evaluation
Opioid receptor affinities were determined by equilibrium radioligand binding assays
as previously described [19,26,33] with membranes from Chinese hamster ovary (CHO) cells
stably expressing rat KOR, rat MOR or mouse DOR using the radioligands [3H]diprenorphine,
[3H][d-Ala2,N-MePhe4,glyol]enkephalin (DAMGO) and [3H]DPDPE, respectively. Following
determination of IC50 values by nonlinear regression using Prism software (GraphPad Software
Co., La Jolla, CA, USA) Ki values were calculated using the Chen and Prusoff equation [34]. The results
are presented as the mean ± SEM from at least three separate experiments each performed in triplicate.
Agonist stimulation of [35S]GTPγS binding to membranes from CHO cells stably expressing KOR
or MOR was assayed as described previously [19,26,35]. The macrocyclic tetrapeptides were screened
at 10 µM for efficacy compared to the reference full agonists dynorphin A-(1-13) amide for KOR and
DAMGO for MOR. The stereoisomers all exhibited negligible stimulation of GTPγS binding at both
KOR and MOR.
4.6. In Vivo Testing
4.6.1. Animals and Drug Administration
Adult male wild-type C57BL/6J mice weighing 20–25 g were obtained from Jackson Labs
(Bar Harbor, ME, USA). Food pellets and distilled water were available ad libitum. All mice were kept
on a 12 h light-dark cycle and were housed and cared for in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals. All results of animal testing are reported in
accordance with ARRIVE guidelines [36].
For intracerebroventricular (i.c.v.) administration the macrocyclic tetrapeptides were dissolved
in dimethyl sulfoxide (DMSO), followed by addition of sterile saline (0.9%) so that the final vehicle
was 50% DMSO and 50% saline, and the i.c.v. injections performed as described previously [26].
This concentration of DMSO was not observed to have antinociceptive or behavioral effects in previous
use [9,19,21]. For per os (p.o.) administration the macrocyclic tetrapeptides were administered in 10%
Solutol in 0.9% saline. All solutions for animal administration were prepared fresh daily.
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4.6.2. Antinociceptive Testing
The 55 ◦C warm-water tail-withdrawal assay was performed in mice as previously described [37],
with the latency of the mouse to withdraw its tail from the water taken as the endpoint (a cut-off time
of 15 sec was used in this assay). Antinociception was calculated according to the following formula:
% antinociception = 100 × (test latency − control latency)/(15 − control latency). Tail-withdrawal data
points are the means of 8–16 mice, unless otherwise indicated, with SEM shown by error bars.
The opioid receptor involvement in the agonist activity of the macrocyclic peptides was determined
by pretreating mice with a single dose of β-funaltrexamine (β-FNA, 10 mg/kg, i.p.) or nor-BNI
(10 mg/kg, i.p.) 24 h in advance of administration of a dose of a macrocyclic tetrapeptide. Additional
mice were pretreated with a single dose of naloxone (30 mg/kg, s.c.) or naltrindole (20 mg/kg, i.p.)
20 min in advance of administration of the macrocyclic tetrapeptide.
To determine antagonist activity, mice were pretreated with the macrocyclic tetrapeptide 140 min
prior to the administration of the MOR-preferring agonist morphine (10 mg/kg, i.p.), KOR-selective
agonist U50,488 (10 mg/kg, i.p.) or DOR-selective agonist SNC-80 (100 nmol, i.c.v.); at this time
the antinociceptive activity of the stereoisomers had dissipated. Antinociception produced by these
established agonists was then measured 40 min after their administration.
4.6.3. Acute Antinociceptive Tolerance Determination
A standardized state of tolerance was induced by administration of morphine or test compound at
times 0 and 8 h [25,38,39] to quantitatively evaluate development of acute opioid tolerance. This assay
was used to efficiently measure the potential of compounds to cause tolerance using a minimum amount
of compound while yielding reliable results. Mice were administered an ED50 dose (i.c.v.) of test
compound in the morning (time = 0) and a second dose (varying between 0.1–300 nmol, i.c.v.) 8 h later.
The degree of tolerance was calculated from the shift in ED50 value from the singly- to repeatedly-treated
condition [40]. All compounds were administered i.c.v., with antinociception assessed 30 min after
injection of morphine or at the time of peak antinociceptive effect of the macrocyclic tetrapeptides,
as determined in their initial antinociceptive characterization.
4.6.4. Coordinated Locomotor Activity
The stereoisomers were tested for their possible impairment of locomotor coordination in the
rotarod assay as described previously [9,21]. Locomotor activity was recorded using an automated,
computer-controlled rotarod apparatus (San Diego Instruments, San Diego, CA, USA). Mice were first
habituated to the rotarod over seven trials, with the last trial serving as the baseline response. Mice so
habituated were then administered a 10 mg/kg dose of a stereoisomer (p.o.), U50,488 (i.p.), or vehicle
15 min prior to assessment in accelerated speed trials (180 s max latency at 0–20 rpm) performed every
10 min over a 60 min period. Mice were thus tested a total of 14 trials (seven habituation trials prior to
treatment + seven drug trials). Decreased latencies to fall in the rotarod test indicate impaired motor
coordination/sedation.
4.6.5. Respiration and Ambulation
Respiration rates (in breaths per minute) and animal locomotive activity (as ambulations) were
assessed using the Oxymax/CLAMS system (Columbus Instruments, Columbus, OH, USA) as described
previously [9,25]. Mice were habituated to their individual sealed housing chambers for 60 min before
testing. Mice were administered stereoisomer (10 mg/kg, p.o.), morphine (10 mg/kg, i.p.), U50,488
(10 mg/kg, i.p.), or vehicle, as indicated, and five min later confined to the CLAMS testing chambers.
Pressure monitoring within the sealed chambers measured frequency of respiration. Infrared beams
located in the floor measured locomotion as number of beam breaks. Respiration and locomotive
data were averaged over 10 min periods for 60 min post-injection of the test compound. Data is
presentenced as % vehicle response ± SEM, ambulation or breaths per minute.
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4.6.6. Evaluation of Potential Conditioned Place Preference and Conditioned Place Aversion
An automated, balanced three-compartment place conditioning apparatus (San Diego Instruments,
San Diego, CA, USA) and a 2-day counterbalanced place conditioning design was used similar to
methods previously described [21]. The amount of time subjects spent in each of the three compartments
was measured over a 30 min testing period. Prior to place conditioning an initial preference test
was performed in which the animals could freely explore all open compartments; the animals did
not demonstrate significant differences in their time spent exploring the outer left versus right
compartments (p > 0.05, Student’s t-test). For place conditioning mice were administered 0.9% saline
(i.p.) and consistently confined in a randomly assigned outer compartment: half of each group in the
right chamber, and half in the left chamber. Four hours later, mice were administered test compound
and confined to the opposite compartment for 40 min. To determine if 3 or 5 (10 mg/kg, p.o.) produced
CPP or CPA, mice were place conditioned in this way for two days, with a final preference test taken
on the fourth day, as this has been shown to produce dependable morphine CPP and U50,488-induced
CPA [41]. Additional groups of mice were placed conditions with morphine or U50,488 (10 mg/kg, i.p.)
as positive controls.
4.7. Statistical Analysis
All dose-response lines were analyzed by regression, and ED50 (effective dose producing
50% antinociception) values and 95% confidence intervals (C.I.) determined using individual data
points from graded dose-response curves with Prism 8.0 software (GraphPad, La Jolla, CA, USA).
Percent antinociception was used to determine within group effects and to allow comparison to baseline
latency in tail-withdrawal experiments. The statistical significance of differences between ED50 values
was determined by evaluation of the ED50 value shift via nonlinear regression modeling with Prism
software. Significant differences in behavioral data were analyzed by ANOVA (one-way or two-way
with repeated measures (RM), as appropriate). Significant results were further analyzed with Sidak’s,
Tukey’s, or Dunnett’s multiple comparison post hoc tests, as appropriate. Data for conditioned place
preference experiments were analyzed by two-way RM ANOVA, with analyses examining the main
effect of conditioned place preference phase (e.g., pre- or post-conditioning) and the interaction of drug
pretreatment. Significant effects were further analyzed using Sidak’s HSD post hoc testing. All data are
presented as mean ± SEM, with significance set at p < 0.05.
5. Patents
J.V. Aldrich and S. Senadheera, Cyclic Tetrapeptide Stereoisomers, U.S. Patent 10,259,843 B2, 2019,
and European patent EP3,166,625, 23019.
Supplementary Materials: The following are available online, Figure S1: Time-course of antinociceptive activity
in the 55 ◦C warm-water tail-withdrawal assay following (A) i.c.v. administration and (B) oral administration in
C57Bl/6J mice of a maximally efficacious dose. Points represent average % antinociception ± SEM from 4–16 mice
for each set presented, Figure S2. Effects of the U50,488 or morphine on (A) respiration and (B) ambulation
in C57BL76J mice. Respiration and ambulation were monitored after administration of U50,488 or morphine
(10 mg/kg, i.p.) using the CLAMS/Oxymax system. Data from 9–18 mice presented as % vehicle response ± SEM;
breaths per minute, BPM (A) or ambulation, XAMB (B). * significantly different from response of saline alone
(p < 0.05); two-way RM ANOVA with Dunnett’s multiple comparison post hoc test., Figure S3. Evaluation of
acute antinociceptive tolerance in the 55 ◦C warm-water tail-withdrawal assay following i.c.v. administration of
morphine, (A) CJ-15,208, (B) 1, (C) 2, (D) 3, (E) 4 or (F) 5. All points represent antinociception at peak response in
naïve mice (Time 0 h) and mice that were previously administered an ED50 dose of test compound (as listed) prior
to additional administration of a graded dose of test compound eight hours later (Time 8 h). Points represent
average % antinociception ± SEM from 8–16 mice for each set presented, Figure S4. HPLC chromatograms of the
peptides in 15–55% MeCN over 40 min with 0.1% TFA, detection at 214 nm, (A) 1, (B) 2, (C) 3, (D) 4 and (E) 5,
Figure S5. HPLC chromatograms of the peptides in 30–70% MeOH over 40 min with 0.1% TFA, detection at
230 nm, (A) 1, (B) 3, (C) 4 and (D) 5.
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